Target intelligence / Profile preview

Lymphatic capillary and regional lymph node

Molecular classification
Other (structural component of tissue; not a molecule or receptor)
01

Overview

Lymphatic capillaries are thin-walled microvessels originating blindly in the interstitial space of tissues, designed to collect excess interstitial fluid, macromolecules, and cells for return to circulation via larger lymphatic vessels and, ultimately, the blood. Regional lymph nodes are discrete encapsulated organs distributed along these vessels; they filter lymph, trap pathogens, and mediate immune responses. Together, these structures maintain fluid homeostasis, support immune surveillance, and play a key role in disease processes including cancer metastasis and chronic inflammation. Recent therapeutic strategies are beginning to target lymphatic structures at the tissue level by amplifying lymphangiogenesis or modulating immune mechanisms to treat lymphedema, metastatic cancer, and neurological conditions. However, as a drug target, the term "lymphatic capillaries and regional lymph nodes" is conceptually and operationally imprecise and should be replaced by more specific molecular or cellular targets (such as VEGFR-3, lymphatic endothelial markers, or immune cell subsets).

Other names
lymph capillarylymph nodelymphatic vesselslymphatic tissue
02

Mechanism of action

Promotion or inhibition of lymphangiogenesis via VEGF-C/VEGFR-3 pathway; Modulation of immune responses via Th2 cytokines (IL-4/IL-13); Enhancement of lymphatic drainage or obstruction removal.

03

Biological functions

Fluid homeostasisImmune responseFiltration of extracellular fluid and pathogensLymphangiogenesisFat absorption (via lacteals)
04

Disease associations

LymphedemaCancer metastasis (especially breast, prostate, ovarian, and others)InflammationInfectionNeurodegenerative disease (via meningeal and CNS lymphatic drainage)
05

Safety considerations

Off-target effects on normal lymphatic functionChronic edema or impaired drainage after interventionImmune suppression or dysregulationSurgical complications (for physical interventions)
06

Interacting drugs

VEGF-C (gene therapy, recombinant protein, mRNA-LNPs for lymphangiogenesis)

3 more in the full profile.

07

Biomarkers

Lymphatic vessel densityVEGF-C expressionLymph node size or imaging markersLymphatic flow or function (diagnosed by imaging or functional assays)

Beyond the preview

Go deeper on Lymphatic capillary and regional lymph node.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lymphatic capillary and regional lymph node.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call